Novo, Lilly weight-loss drugs should be first option obesity treatments, European doctors (...)
Semaglutide, the active ingredient in Novo's Wegovy and Ozempic, and tirzepatide, sold as Zepbound and Mounjaro by Lilly, are so effective that they should be the first choice in almost all cases when substantial weight loss is necessary, according to a new guideline from the European (...)
Site référencé: The Economic Times
The Economic Times
Gold gains for 9 consecutive months till Navratri. Could Rs 2 lakh target come sooner ?
24/09/2025
Kremlin says Exxon is not the only company interested in returning to Russia
24/09/2025
Jaffar Express attacked : Repeated attacks reveal Pakistan's railway security failures
24/09/2025
Markets near short-term bottom after four-day correction : Rohit Srivastava
24/09/2025
Adani Power shares fall 11% in 2 days after a 35% rally. Should you buy the dip ?
24/09/2025
Maruti Suzuki shares jump 2% to hit 52-week high after Goldman Sachs upgrade, 15% upside potential seen
24/09/2025
